During the past decade, National Hospital Organization Tokyo Medical Center conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 4 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 2 clinical trials were completed. i.e. 40% of trials that started reached the finish line.

Out of the total clinical trials conducted in "National Hospital Organization Tokyo Medical Center" #1 sponsor was "Janssen Research & Development, LLC" with 3 trials, followed by "Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan" with 3 trials sponsored, "Janssen Pharmaceutical K.K." with 2 trials sponsored, "Shire" with 2 trials sponsored and "Bristol-Myers Squibb" with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "National Hospital Organization Tokyo Medical Center" #1 collaborator was "Boehringer Ingelheim" with 1 trials as a collaborator, "Eisai Co., Ltd." with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Kagawa University" with 1 trials as a collaborator and "Kurosawa Hospital" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "National Hospital Organization Tokyo Medical Center" are "Essential Thrombocythemia (ET)" (2 trials), "Prostate Cancer" (2 trials), "Bone Metastasis" (1 trials), "Breast Cancer" (1 trials) and "Cancer Pain" (1 trials). Many other conditions were trialed in "National Hospital Organization Tokyo Medical Center" in a lesser frequency.

Most popular intervention types in "National Hospital Organization Tokyo Medical Center" are "Drug" (14 trials), "Biological" (1 trials), "Other" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Guselkumab" (2 trials), "Adalimumab" (1 trials), "Amivantamab" (1 trials) and "Anagrelide Hydrochloride" (1 trials). Other intervention names were less common.

The vast majority of trials in "National Hospital Organization Tokyo Medical Center" are 14 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "National Hospital Organization Tokyo Medical Center". undefined are not yet recruiting, 3 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in National Hospital Organization Tokyo Medical Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in National Hospital Organization Tokyo Medical Center, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".